The potential of olaparib in combination therapies has also been evaluated in chemotherapy settings, although PARP1 inhibition combined with histone lysine demethylase (KDM) inhibitors alone did not yield substantial efficacy in HNSCC cells. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.